4DMedical, Richlink Venture Captial Fund invested Australian medical technology company specializing in medical imaging innovation software, announced it has received clearance from the U.S. Food & Drug Administration to market its XV Technology™, a patented four-dimensional lung imaging process that rapidly and automatically analyses any functional lung impairment from a single X-ray. 4DMedical’s U.S. operations are based in Woodland Hills, California.

Original article:  https://www.dotmed.com/news/story/51325?p_begin=1